Andere talen RepliCel Life Sciences Inc.

Aandelen

REPCF

CA76027P4006

Beurs gesloten - OTC Markets Andere beurzen 16:20:42 15-03-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0428 ^USD	+4,99%		-.--%	-4,89%

2023	RepliCel Life Sciences Inc. rapporteert de winstresultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2023	CI
2023	RepliCel Life Sciences Inc. Rapporteert winstresultaten voor het tweede kwartaal en de zes maanden eindigend op 30 juni 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Canadian Investment Regulatory Organization Trading Halt - RP	08/05
RepliCel Life Sciences : Announces Secured Loan Agreement	18/04
RepliCel Life Sciences Inc. Announces Secured Loan Agreement	18/04
RepliCel Life Sciences : announces a Letter of Intent for Asset Purchase Agreement - Form 6-K	20/03
RepliCel Life Sciences : Letter of Intention (Asset Purchase)	18/03
Canadian Investment Regulatory Organization Trading Halt - RP	15/03
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	30/11
RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11
RepliCel Life Sciences : Arbitration decision	16/11
REPLICEL LIFE SCIENCES : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	24-10-23
RepliCel Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24-10-23
RepliCel Life Sciences : AGM 2023 Zoom Link and Materials	22-09-23
Replicel Life Sciences Inc. Announces That Peter Lowry Will Not Be Standing for Re-Election as A Director	30-08-23
RepliCel Life Sciences : Notice of Meeting and Record Date - Form 6-K	17-08-23
RepliCel Life Sciences Inc. Appoints Jamie Mackay to the Board of Directors	17-08-23
RepliCel Life Sciences Inc. Announces Chief Financial Officer Changes	17-08-23
REPLICEL LIFE SCIENCES : STATEMENT OF EXECUTIVE COMPENSATION - Form 6-K	10-08-23
RepliCel Life Sciences : CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	31-05-23
RepliCel Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	30-05-23
RepliCel Life Sciences : Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options - Form 6-K	18-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RepliCel Life Sciences Inc.

Aandelen

REPCF

CA76027P4006

Andere talen

Filters